Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
32 /100
MEDIUM RISK
Score updated Aug 28, 2026

IKT — Inhibikase Therapeutics, Inc. Dilution Risk Tracker

Track IKT dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track IKT — Get alerts when the score changes →

As of August 28, 2026, Inhibikase Therapeutics, Inc. (IKT) has a DilutionWatch DilutionScore of 32/100, rated MEDIUM dilution risk. Inhibikase Therapeutics, Inc. has a market capitalization of $231.06M, 139.54M shares outstanding, 104 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
0
📊 Float Risk
30
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

Watch
Minor dilution signals detected
model est. 15%
🔄 Reverse Split model est. 30%
• 50-day avg $1.79 approaching $1 threshold
🔔 Track IKT — Get forecast alerts →

Market Data

Market Cap$231.06M
Shares Outstanding139.54M
Float86.88M
Cash$306.61M
Debt$381.8K
Short InterestN/A

Institutional Holdings

QoQ: ↑ 9.6% shares (2026Q1 vs prior)
104 institutional holders · 125.60M shares
#1 Sands Capital Alternatives, LLC 13.02M shares
#2 Soleus Capital Management, L.P. 10.88M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 8.90M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest19.14M
Days to Cover21.5
% of Float22.0%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2020-12-28
Full SEC filing analysis available with free account

Recent News

No recent news

Factual IKT Dilution Snapshot

Inhibikase Therapeutics, Inc. (IKT) has a DilutionScore of 32/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track IKT Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking IKT — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for IKT
IKT FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.